Ascendis Pharma A (ASND) Free Cash Flow (2014 - 2026)

Ascendis Pharma A has reported Free Cash Flow for 13 years, with the latest figure at -$9.0 million in Q1 2026.

• Quarterly Free Cash Flow rose 39.96% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$138.5 million (up 41.05% YoY) and the FY2025 annual result came in at -$146.4 million, up 55.26% from the prior year.
• Free Cash Flow improved to -$9.0 million in Q1 2026 per ASND's latest filing, from -$123.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $2.5 million in Q3 2025 and troughed at -$166.3 million in Q2 2023.
• A 5-year average of -$88.0 million and a median of -$96.5 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 103.56% in 2024, then surged 104.12% in 2025.
• Over 5 years, Free Cash Flow stood at -$140.7 million in 2022, then surged by 67.47% to -$45.8 million in 2023, then plunged by 103.56% to -$93.2 million in 2024, then sank by 32.79% to -$123.7 million in 2025, then jumped by 92.69% to -$9.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$9.0 million, -$123.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.